Australia New Zealand Gynaecological Oncology Group

What Australia New Zealand Gynaecological Oncology Group does

The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the peak national gynaecological cancer clinical trials organization for Australia and New Zealand, established in 2000 by a network of volunteer gynaecological cancer specialists led by Professor Michael Friedlander AM. The organization operates as an independent, non-profit charitable entity incorporated in New South Wales, Australia, with offices in Sydney (headquarters at Level 6, Lifehouse, Camperdown) and Melbourne. ANZGOG's mission is to improve outcomes and quality of life for women with gynaecological cancer by conducting and promoting cooperative clinical trials and multidisciplinary research into the causes, prevention, and treatments of gynaecological cancers. Since founding it has enabled 60 studies including 37 clinical trials, treating approximately 4,000 women across 59 hospital sites, and currently serves over 1,500 members representing clinical, allied health, and pure research specialties. Two consecutive leaders (Clare Scott AM, Alison Brand AM) have received Member of the Order of Australia, and the OUTBACK cervical cancer trial was presented at the ASCO 2021 Plenary Session as "immediately practice-changing."

ANZGOG's core research portfolio comprises three flagship initiatives: the OASIS Initiative (Ovarian cancer Alliance for Signal-Seeking clinical trials, launched 2015 in collaboration with the Australian Ovarian Cancer Study), the EDEN Initiative (EnDomEtrial caNcer Research Initiative, implemented 2021 to address rising endometrial cancer incidence), and TR-ANZGOG (Translational ANZGOG, launched 2020 to integrate biospecimen collection and analysis into clinical trials). The clinical trials portfolio covers ovarian, endometrial, cervical, vulvar, and vaginal cancers, with a teletrials program extending access to regional and remote patients. Education and awareness programs include Survivors Teaching Students (11,000+ students reached since 2017), the On the Down Low podcast, and the Annual Scientific Meeting. The fundraising arm WomenCan operates the Team Teal harness racing campaign, which raised close to AUD 400,000 in 2022. Pharmaceutical sponsors include AstraZeneca, BeiGene and Amplia Therapeutics; international consortium memberships include GCIG (32 member countries) and APGOT.

ANZGOG's revenue model is grant- and philanthropy-driven rather than product-based, as clinical trials are delivered at hospital sites at no direct cost to patients. Revenue streams comprise government grants (Medical Research Future Fund, Cancer Australia, Cancer Council Queensland), pharmaceutical trial support, and public donations and bequests managed through WomenCan. Notable recent grants include AUD 4.3 million from the MRFF across HyNOVA, ADELE and PARAGON-II; a AUD 2 million Cancer Council Queensland grant for the ECHO exercise-intervention trial; and over AUD 21.2 million in cumulative government grant funding via the University of Sydney since 2002. Audited FY2021 total revenue from continuing operations was AUD 3,884,109. The organization is governed by a Board of Directors chaired by Professor Clare Scott AM and is not publicly traded; it has no parent company and no external equity investors.

Name

Australia New Zealand Gynaecological Oncology Group

Legal name

Australia New Zealand Gynaecological Oncology Group

Website

https://anzgog.org.au

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

ANZGOG is the peak national gynaecological cancer clinical trials organization for Australia and New Zealand. Operating as a non-profit, it conducts cooperative clinical trials and translational research across 59 hospital sites, serving women with gynaecological cancers.

Ownership category

akta.pro rank

Product category

Clinical Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Health Services (8000)

akta.pro industry

PRIMARYHLAKAFAF

Gynecologic Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Hematology & Oncology

SECONDARYHLAKAJAD

Gynecologic Oncology

Healthcare & Life Sciences/Specialist Medical Practice/Obstetrics & Gynecology (OB/GYN)

SECONDARYHLAFAJAK

Gynecologic Oncology & Women’s Cancer Centers

Healthcare & Life Sciences/Healthcare Providers & Systems/Women’s & Children’s Health Providers

Keywords

• Clinical trial management
• Gynaecological cancer research
• Cooperative oncology group
• Translational cancer research
• Clinical research services

Headquarters

HQ city

Camperdown

HQ country

Australia

HQ region

Oceania

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Government Grants: Government grant funding including MRFF grants, Cancer Australia support, and Medical Research Future Fund grants
2. Pharmaceutical Support: Pharmaceutical company sponsors support for clinical trials including AstraZeneca, BeiGene, and others
3. Donations and Philanthropy: Public donations, bequests, and community fundraising through WomenCan and Team Teal campaigns
4. Harness Racing Partnerships: Partnership with harness racing industry through Team Teal campaign raising funds for research

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

ANZGOG is the peak national gynaecological cancer clinical trials organisation for Australia and New Zealand. It designs, conducts, and promotes cooperative clinical trials and multidisciplinary research into the causes, prevention, and treatments of gynaecological cancers (ovarian, endometrial, cervical, vulvar). It operates a portfolio of clinical trials across 59 hospital sites and runs associated research initiatives, educational programs, and a fundraising arm (WomenCan).

Product overview

ANZGOG (Australia New Zealand Gynaecological Oncology Group) is the peak national gynaecological cancer research organisation for Australia and New Zealand, operating as a cooperative clinical trials group rather than a traditional product company. Its portfolio includes research initiatives (OASIS Initiative for ovarian cancer signal-seeking trials, EDEN Initiative for endometrial cancer, and TR-ANZGOG for translational research), a clinical trials portfolio covering ovarian, endometrial, cervical, and vulvar cancers, education programs (Survivors Teaching Students, On the Down Low podcast, Annual Scientific Meeting), the WomenCan fundraising arm, and the Fund for New Research grant program. The organization connects clinical research with laboratory science to improve outcomes for women with gynaecological cancers.

Differentiator

Problem solved

Functional benefit

Brands

• OASIS Initiative: Ovarian cancer Alliance for SIgnal-Seeking clinical trials - a collaborative research program between ANZGOG and the Australian Ovarian Cancer Study to undertake signal-seeking trials that can lead to larger randomized trials.
• EDEN Initiative
• On the Down Low Podcast
• Survivors Teaching Students (STS)
• Team Teal
• TR-ANZGOG

Products and services

• OASIS Initiative A collaborative research program between ANZGOG and the Australian Ovarian Cancer Study that undertakes small signal-seeking trials to show sufficient evidence of clinical activity to enable larger randomised trials. Intended for ovarian cancer researchers and clinicians.
• EDEN Initiative A collaborative research program addressing unmet needs of endometrial cancer patients in Australia and New Zealand, focusing on prevention, risk assessment, early diagnosis, surgical innovations, adjuvant and recurrent treatments, survivorship, translational research, and advocacy.
• TR-ANZGOG A world-class translational research initiative that integrates biospecimen collection and processing/analysis into ANZGOG clinical trials, enabling laboratory research alongside clinical trial activity for gynaecological cancers.
• Fund for New Research A grant program that promotes the development of investigator-led studies from initial concept to full study, awarding grants of $50,000, $30,000 and $20,000 for pre-clinical, pilot, and small clinical trials. Aimed at gynaecological cancer researchers.
• Survivors Teaching Students A volunteer education program that brings gynaecological cancer survivors and caregivers into classrooms of health professional students to share lived experiences with the diseases.
• ANZGOG Clinical Trials Portfolio

Quantifiable outcome

• 60 studies including 37 clinical trials conducted since 2000, treating close to 4,000 women
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered minor and core.

• Amplia TherapeuticsminorStrategic or Co-development Partner · 12 May 2026Partnership to expand into ovarian cancer research with ANZGOG supporting Amplia's FAK inhibitor narmafotinib study for combination therapy in ovarian cancer.
• University of Sydney NHMRC Clinical Trials CentrecoreStrategic or Co-development Partner · 12 November 2025Major collaborator in SOLACE2 clinical trial evaluating PARP inhibitor therapy with blood test companion diagnostic. ANZGOG provided funding and support for translational program.
• RMIT UniversitycoreStrategic or Co-development Partner · 12 November 2025RMIT led research on new blood test for PARP inhibitor therapy targeting, developed patented biomarkers through SOLACE2 trial collaboration.
• WEHI (Walter and Eliza Hall Institute)coreStrategic or Co-development Partner · 12 November 2025WEHI provided joint-senior authorship and research collaboration on SOLACE2 trial investigating immune response and PARP inhibitor therapy.
• Gynecological Cancer InterGroup (GCIG)coreStrategic or Co-development Partner · 1 June 2021International consortium of 32 member countries. ANZGOG Director Alison Brand AM appointed Chair-Elect, demonstrating global leadership in gynaecological cancer research.
• Harness Racing IndustrycoreGTM or Marketing Partner · 1 February 2021Ongoing partnership with harness racing community through Team Teal campaign raising over $371,000 in 2021 and $300,000-$400,000 in 2022 for research.
• AstraZenecacoreGTM or Marketing Partner · 1 January 2021Pharmaceutical partner providing support for clinical trials and education activities including SOLACE2 trial and webinar series.
• Asia Pacific Gynecological Oncology Trials Group (APGOT)coreStrategic or Co-development Partner · 1 November 2019ANZGOG is inaugural member of APGOT formed to focus on collaborative studies in gynaecological cancer within Asia Pacific region.
• Mario Negri Gynecology Oncology Group (MaNGO)coreStrategic or Co-development PartnerInternational collaboration on AtTEnd endometrial cancer clinical trial testing atezolizumab in combination with chemotherapy.
• NHMRC Clinical Trials CentrecoreStrategic or Co-development PartnerLong-term relationship with CTC at University of Sydney acting as sponsor for larger trials. Collaborative agreement supports operation of ANZGOG trials.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cancer Australia: Australian Government cancer control agency providing grant funding that supports ANZGOG research. Cancer Australia is a broader institutional incumbent and key funder/partner rather than a direct competitor, but its policy priorities shape ANZGOG's funding environment.
• Cancer Council Australia: Australia's peak national non-government cancer control organisation. Cancer Council is a broader incumbent in cancer research funding and policy in Australia, with overlapping government-relations activity but a much wider remit than ANZGOG's gynaecological cancer focus.

Others

• Gynecologic Cancer InterGroup (GCIG): International consortium of 32 member countries coordinating gynaecological cancer clinical trials. ANZGOG is a member and its Director serves as Chair-Elect, making GCIG a peer consortium and a key channel for cross-border trial collaboration rather than a direct competitor.

Direct peers

• Ovarian Cancer Research Alliance (OCRA): US-based ovarian cancer research and advocacy organisation from which ANZGOG licenses the Survivors Teaching Students program. OCRA is a peer in gynaecological/ovarian cancer research funding, advocacy, and patient-education programming, with a comparable community-driven model.
• Canadian Cancer Trials Group (CCTG): Canadian cooperative oncology trials group with an active gynecological cancer committee running multi-site trials. CCTG is a direct functional peer to ANZGOG — a national cooperative trials organisation running investigator-initiated and pharma-sponsored gynaecological cancer studies — though in a different geography.
• Mario Negri Gynecology Oncology Group (MaNGO): Italian gynaecological cancer clinical trials cooperative that collaborates with ANZGOG on the AtTEnd endometrial cancer trial. MaNGO is a close international peer with a similar cooperative-trial model, comparable patient-base focus, and overlapping sponsorship model with pharma partners.
• NRG Oncology: US National Cancer Institute-sponsored cooperative group formed from the merger of Gynecologic Oncology Group (GOG), NSABP, and RTOG, running multi-site gynaecological cancer clinical trials. NRG is the most direct functional analogue to ANZGOG as a national cooperative gynaecological cancer trials organisation, just at significantly larger scale and US-focused.
• Asia Pacific Gynecological Oncology Trials Group (APGOT): Asia-Pacific regional gynaecological cancer trials consortium of which ANZGOG is an inaugural member. APGOT is a direct regional peer focused on collaborative gynaecological cancer studies across Asia-Pacific, with overlapping geographic remit and member institutions.

Emerging players

• WEHI (Walter and Eliza Hall Institute of Medical Research): Australia-based medical research institute whose Ovarian and Rare Cancer Laboratory is led by ANZGOG Chair Prof Clare Scott AM. WEHI is a research partner and overlapping player in translational ovarian cancer science, including joint senior authorship on SOLACE2.
• Cure Our Ovarian Cancer (COCO): New Zealand-based ovarian cancer advocacy and research funding organisation. COCO is a smaller regional peer with similar ovarian cancer research-fundraising and community-advocacy activity, primarily serving New Zealand patients.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/anzgog
• YouTubeyoutube.com/@anzgog
• LinkedInlinkedin.com/company/anzgog
• Facebookfacebook.com/anzgog
• Instagraminstagram.com/anzgog

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Australia New Zealand Gynaecological Oncology Group